Journal
PSYCHIATRIC CLINICS OF NORTH AMERICA
Volume 39, Issue 1, Pages 125-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.psc.2015.09.006
Keywords
Bipolar depression; Inflammation; Innate immune system; NAC; NSAIDs; Infliximab; Minocycline; Antiinflammatory
Categories
Funding
- Lundbeck
- AstraZeneca
- Pfizer
- Shire
- Otsuka
- Bristol-Myers Squibb
- National Institute of Mental Health
- Stanley Medical Research Institute
- Canadian Institutes of Health Research
- Brain and Behavior Research Foundation
- Elli Lilly
- Janssen Ortho
- Sunovion
- Takeda
- Forest
Ask authors/readers for more resources
The pathophysiology of bipolar disorder (BD) remains poorly understood. Current psychopharmacologic treatments are often poorly tolerated and carry high rates of treatment resistance. Mounting evidence has suggested that innate immune system dysfunction may play a role in the pathophysiology of BD. Elevated proinflammatory cytokine levels have been identified. The innate immune system is a novel therapeutic target in BD. Lithium has been shown to have antiinflammatory properties. Further research is needed to establish the role of antiinflammatory agents in the treatment of BD; however, evidence from several clinical trials indicates that antiinflammatory agents may be incorporated into clinical practice soon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available